Oxford Biomedica (LSE: OXB) plunges 15% as 2026 revenue guidance falls

Oxford Biomedica plc (LSE: OXB) became one of the London market’s sharpest fallers on August 7 after the cell and gene therapy manufacturing specialist cut its 2026 revenue guidance to £180 million to £200 million from £220 million to £240 million. The shares closed 14.55% lower at 505p after falling as low as 446.5p, with 6.61 million shares changing hands compared with roughly 247,000 during the previous session. Management attributed the downgrade primarily to delayed client programmes, changes in ordering behaviour and a roughly six month delay in operational readiness at its Durham, North Carolina manufacturing facility. The next major test comes on September 22, when Oxford Biomedica reports detailed half year results and investors can assess how much of the downgrade reflects timing rather than a weakening long term demand outlook.

The selloff creates a clearer valuation tension than Oxford Biomedica faced only weeks ago. The company remains committed to medium term revenue growth of 25% to 30% and an ambition to generate around £500 million of annual revenue by 2030, yet the first major guidance reset of 2026 has raised the burden of proof around execution. At 505p, OXB is valued at approximately £611 million, making successful conversion of its order book, utilisation of recently expanded capacity and recovery in margins increasingly important.

What does Oxford Biomedica currently do and why is viral vector manufacturing valuable?

Oxford Biomedica is now focused on operating as a contract development and manufacturing organisation rather than developing a broad proprietary drug pipeline of its own. The company works with pharmaceutical and biotechnology customers developing cell and gene therapies, providing the viral vectors required to deliver genetic material into patients’ cells.

Its capabilities span lentiviral vectors, adeno associated virus vectors, adenoviral vectors and other viral vector technologies. The company’s current technology portfolio includes its LentiVector platform, inAAVate platform and AdenoVate platform, alongside analytical, process development and manufacturing capabilities.

The business operates across development and manufacturing facilities in Oxford, Bedford and Durham in the United States, and Lyon and Strasbourg in France. This geographic footprint is intended to place manufacturing capacity close to major biotechnology clusters while allowing customers to progress programmes from early development towards clinical and eventually commercial production.

Viral vector manufacturing can become particularly valuable when a customer’s therapy moves into later stage trials or commercial use. Early programmes may require relatively small development batches, while approved products can create recurring manufacturing demand over several years.

That creates operating leverage for a CDMO with existing capacity. A manufacturing facility carries substantial fixed costs, meaning additional production can improve margins once utilisation reaches sufficient levels. The opposite is also true. Capacity that remains underused can weigh heavily on profitability, which explains why delays at Durham matter financially even if the underlying technology remains attractive.

Why did OXB cut its 2026 revenue guidance by roughly £40 million at the midpoint?

Oxford Biomedica now expects 2026 revenue of £180 million to £200 million, compared with its previous £220 million to £240 million range. At the midpoint, expected revenue has therefore fallen from £230 million to £190 million, a reduction of approximately £40 million or 17%.

Management identified changes in client ordering behaviour as a central reason for the revision. These included delays to programme timelines and changes in the procurement pathway of a large client, which shifted revenue that Oxford Biomedica had expected to recognise during 2026.

The company also disclosed that operational readiness at its recently acquired Durham facility had been delayed by approximately six months. That facility was acquired to expand Oxford Biomedica’s United States manufacturing capability, particularly for later stage and commercial scale viral vector programmes.

The earnings impact goes beyond lost or deferred revenue. Oxford Biomedica had previously targeted an operating EBITDA margin around 10% for 2026. It now expects a mid single digit percentage margin before one off costs.

That margin reset demonstrates how sensitive the business remains to utilisation. Manufacturing employees, quality systems, specialised equipment and regulated facilities continue generating expenses even if customer programmes move to later periods.

The critical distinction is whether revenue has been delayed or permanently lost. Oxford Biomedica has described programme timing and procurement changes rather than a broad collapse in customer demand. Investors will nevertheless need evidence that postponed work actually converts into future revenue before treating the downgrade simply as a timing issue.

Does the Durham delay undermine Oxford Biomedica’s United States expansion strategy?

The Durham facility was an important part of Oxford Biomedica’s strategy to build a global multi site manufacturing platform. The company acquired the FDA approved commercial scale facility in late 2025 and expected it to strengthen its ability to support customers requiring larger scale manufacturing in the United States.

Durham provides both vector substance and vector product manufacturing capability and complements Oxford Biomedica’s existing Bedford operation. Bedford is more closely focused on process and analytical development, while Durham is intended to support clinical and commercial manufacturing.

The delayed operational readiness does not remove the facility from Oxford Biomedica’s network. It does, however, postpone the point at which the asset can contribute at the level originally expected.

This matters because Oxford Biomedica has already invested capital and management attention into integrating Durham. Every quarter of slower utilisation extends the period before those resources generate their expected returns.

There is still evidence of commercial interest in the facility. Oxford Biomedica announced in July that it had been selected to support an adeno associated virus gene therapy programme for Plowshare Therapies from Durham, while the broader group also has a multi year commercial supply agreement with Bristol Myers Squibb covering lentiviral vectors for CAR T programmes.

Those contracts support the strategic logic of having greater United States capacity, but contract announcements are not substitutes for recognised revenue. The September results need to provide greater clarity on when Durham will become fully operational, what costs remain and how much work is expected to move through the facility during 2027.

Can Oxford Biomedica’s backlog still support its £500 million 2030 revenue ambition?

Oxford Biomedica entered 2026 with a substantial contracted position. At December 31, 2025, revenue backlog stood at approximately £204 million, up about 36% from a year earlier, while contracted client orders reached roughly £224 million.

The company was supporting 48 programmes across 40 clients at the time of its 2025 results, with a growing number progressing into later clinical or commercial stages. That progression is important because later stage programmes generally require larger production volumes and can become more valuable to a manufacturing partner.

Oxford Biomedica also reported a potential business pipeline of approximately US$597 million at the end of 2025. Pipeline figures should not be treated as contracted revenue because opportunities can change, be delayed or never convert into orders. The size nevertheless provides context around the commercial market the company is targeting.

Management used its June Capital Markets Event to set an ambition of generating around £500 million of annual revenue by 2030. It also retained its medium term expectation for revenue growth of approximately 25% to 30% despite the August downgrade.

The mathematical hurdle has now become higher. Revenue of £180 million to £200 million in 2026 means the company must compound from a lower base if it is to reach £500 million within four years.

A recovery remains possible if delayed programmes return, Durham reaches expected utilisation and customers move from development into commercial manufacturing. The risk is that repeated timing changes could turn what appears to be temporary slippage into structurally slower growth.

The September results therefore need to explain how much of the £204 million backlog remains intact, how its expected recognition has shifted and whether new orders are entering the backlog quickly enough to replace revenue being delivered.

Does Oxford Biomedica have enough financial capacity to absorb slower 2026 growth?

Oxford Biomedica ended 2025 with approximately £96.9 million of cash and cash equivalents, up from £60.7 million a year earlier. The stronger position followed an equity raise of approximately £60 million during 2025 and changes to its financing arrangements.

The company also entered a four year senior secured financing agreement with Oaktree providing up to US$125 million. An initial US$60 million was made available, with further tranches subject to specified conditions.

The financing gives Oxford Biomedica greater capacity to invest in its manufacturing platform, but borrowing is not equivalent to operating cash generation. Interest, repayment obligations and covenant requirements mean the long term financial model still depends on customer revenue translating into sustainable cash flow.

Oxford Biomedica generated positive underlying operating EBITDA in 2025 after several years of losses, marking an important step in its transition towards a commercially focused CDMO. However, 2026 was already expected to be weighted towards the second half because of planned maintenance, technology transfers and Durham integration.

The guidance reduction makes cash conversion more important. Slower revenue can reduce the operating leverage expected from the company’s expanded manufacturing base, while many facility and workforce costs cannot be reduced immediately when customer schedules move.

The current balance sheet provides time to manage the disruption, and the downgrade does not suggest an immediate financing crisis. The commercial question is whether the company can return to stronger revenue growth before investment in its global network places renewed pressure on cash.

How is the market pricing Oxford Biomedica after 6.6 million shares traded?

OXB closed at 505p on August 7 after opening at 460p and trading between 446.5p and 506p. The 14.55% closing decline understated the severity of the initial reaction, with the shares falling by more than 20% during early trading.

Volume reached approximately 6.61 million shares, compared with 247,350 shares during the previous session. The exceptional turnover shows that the guidance cut produced a substantial repricing rather than a low volume move.

The shares were approximately 10% below their August 3 close of 561p and about 13.5% below the July 8 close of 584p. The 52 week range stands at approximately 430p to 950p, leaving OXB only around 17% above the annual low and almost 47% below the high.

Using approximately 121 million shares outstanding, the August 7 close implies an equity value of roughly £611 million.

The stock is now valued at a little over three times the midpoint of revised 2026 revenue guidance. That comparison does not account for cash, debt or the different economics of individual contracts, but it illustrates how sharply valuation expectations have reset.

The 52 week high also contains the effect of earlier takeover interest from EQT, which ultimately chose not to proceed with an offer. That history means the annual trading range should not be interpreted solely as a reflection of Oxford Biomedica’s underlying operating performance.

Retail attention is likely to centre on whether the August decline has overreacted to revenue timing or correctly identified a larger execution problem. The optimistic interpretation is that contracted work has moved rather than disappeared and that underused capacity can produce stronger margins once customers restart. The cautious interpretation is that the downgrade reveals weaker visibility than the previous backlog and guidance suggested.

What must Oxford Biomedica prove at the September 22 half year results?

The first requirement is a clear bridge from the previous £220 million to £240 million revenue forecast to the new £180 million to £200 million range. Investors need to understand how much relates to Durham, how much comes from delayed customer programmes and how much reflects changed procurement arrangements.

The second requirement is an updated backlog. If contracted orders remain strong but revenue recognition has simply moved into 2027, confidence in the medium term story could begin to recover. A weaker backlog or further programme delays would make the £500 million 2030 ambition harder to defend.

Durham will be another major focus. A revised operational timetable, customer-loading plan and expected contribution should help investors judge whether the six month delay is contained.

Cash and operating EBITDA will also matter. The revised mid single digit margin expectation represents a significant reduction from the previous approximately 10% target, so investors will want to understand how much margin can recover when revenue returns.

Oxford Biomedica still possesses valuable viral vector expertise, established pharmaceutical relationships and a manufacturing footprint spanning major biotechnology markets. What has weakened is near term execution visibility.

The September 22 result therefore does not need to restore the old 2026 guidance to improve sentiment. It needs to demonstrate that the delayed revenue remains economically accessible, that Durham has a credible path to utilisation and that the company’s medium term growth assumptions still connect to measurable customer activity. A further downgrade or additional commissioning delay would materially weaken that case.

Key takeaways for investors watching Oxford Biomedica after the August selloff

• Oxford Biomedica plc (LSE: OXB) closed 14.55% lower at 505p on August 7 after cutting 2026 revenue guidance to £180 million to £200 million from £220 million to £240 million.
• Management now expects a mid single digit operating EBITDA margin before one off costs, compared with its previous target around 10%.
• The downgrade reflects delayed client programmes, changes in procurement behaviour and an approximately six month delay in operational readiness at the Durham manufacturing facility.
• Oxford Biomedica retains its medium term growth ambitions, including approximately 25% to 30% revenue growth and around £500 million of annual revenue by 2030.
• The company entered 2026 with approximately £204 million of revenue backlog, £224 million of contracted orders and £96.9 million of cash, giving it a meaningful base from which to manage the disruption.
• OXB traded 6.61 million shares on August 7 and now sits almost 47% below its 52 week high, showing how dramatically expectations have reset.
• The September 22 half year results are the next major proof point, with backlog conversion, Durham readiness, cash generation and revised margin expectations likely to determine whether confidence can rebuild.